Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
04. April 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27. März 2024 16:01 ET
|
Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
20. März 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
06. März 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
28. Februar 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
22. Februar 2024 16:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient...
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
20. Februar 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
06. Dezember 2023 08:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
01. Dezember 2023 11:02 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
22. November 2023 08:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...